ZA975335B - Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors. - Google Patents

Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors.

Info

Publication number
ZA975335B
ZA975335B ZA9705335A ZA975335A ZA975335B ZA 975335 B ZA975335 B ZA 975335B ZA 9705335 A ZA9705335 A ZA 9705335A ZA 975335 A ZA975335 A ZA 975335A ZA 975335 B ZA975335 B ZA 975335B
Authority
ZA
South Africa
Prior art keywords
mirtazapine
pharmaceutical composition
serotonin reuptake
reuptake inhibitors
selective serotonin
Prior art date
Application number
ZA9705335A
Other languages
English (en)
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA975335(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of ZA975335B publication Critical patent/ZA975335B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9705335A 1996-06-19 1997-06-17 Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors. ZA975335B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
ZA975335B true ZA975335B (en) 1998-01-26

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705335A ZA975335B (en) 1996-06-19 1997-06-17 Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors.

Country Status (24)

Country Link
US (1) US5977099A (cs)
JP (2) JP4925074B2 (cs)
KR (1) KR100481254B1 (cs)
CN (1) CN1132581C (cs)
AR (1) AR007609A1 (cs)
AT (1) ATE213159T1 (cs)
AU (1) AU727851B2 (cs)
BR (1) BR9703624A (cs)
CA (1) CA2208199C (cs)
CZ (1) CZ290691B6 (cs)
DE (1) DE69710390T2 (cs)
DK (1) DK0813873T3 (cs)
ES (1) ES2172744T3 (cs)
HU (1) HU225534B1 (cs)
ID (1) ID17051A (cs)
IL (1) IL121076A (cs)
NO (1) NO313177B1 (cs)
NZ (1) NZ328113A (cs)
PL (1) PL188520B1 (cs)
PT (1) PT813873E (cs)
RU (1) RU2181287C2 (cs)
SG (1) SG60073A1 (cs)
TR (1) TR199700522A3 (cs)
ZA (1) ZA975335B (cs)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
CZ296282B6 (cs) * 1997-11-14 2006-02-15 Akzo Nobel N. V. Farmaceutický prostredek
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
KR20020068404A (ko) * 2000-01-19 2002-08-27 악조 노벨 엔.브이. 미르타자핀을 포함하는, 우울증 및 관련 장애 치료용 약물조합물
PL206073B1 (pl) * 2000-02-11 2010-06-30 Organon Nv Zastosowanie mirtazapiny do wytwarzania leku
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ES2296893T3 (es) * 2001-02-12 2008-05-01 N.V. Organon Uso de mirtazapina para el tratamiento de la depresion severa en un paciente humano y portador del gen de la apolipoproteina e4.
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
EP1490073A4 (en) * 2002-03-21 2006-02-01 Martin C Hinz SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM
PL376832A1 (pl) * 2002-11-07 2006-01-09 Torrent Pharmaceuticals Ltd. Sposób wytwarzania polimorficznej postaci chlorowodorku sertraliny
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CN1726039B (zh) 2002-12-27 2010-08-18 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
WO2004075724A2 (en) * 2003-02-21 2004-09-10 Hinz Martin C Serotonin and catecholamine system segment optimization technology
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005023767A2 (en) 2003-09-10 2005-03-17 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
US20080255074A1 (en) * 2004-11-19 2008-10-16 N.V. Organon Drug Combination Comprising A Selective Serotonin Reuptake Inhibitor And A Glucocorticoid Receptor Antagonist For The Treatment Of Depression
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
KR101735466B1 (ko) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2441894B1 (en) 2009-06-09 2015-11-04 Sumitomo Heavy Industries, Ltd. Hybrid excavator and method of controlling hybrid excavator
US8785453B2 (en) * 2009-11-13 2014-07-22 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
MA37714A1 (fr) 2012-06-06 2017-12-29 Orexigen Therapeutics Inc Méthodes de traitement de la surcharge pondérale et de l'obésité

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DE69005992T2 (de) * 1989-12-06 1994-05-05 Akzo Nv Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen.
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
KR20010030860A (ko) * 1997-10-03 2001-04-16 캐리 메디컬 코퍼레이션 니코틴 리셉터 길항제, 및 항-진정제 또는 항-불안 약물을함유하는 니코틴 중독치료용 조성물

Also Published As

Publication number Publication date
ATE213159T1 (de) 2002-02-15
HUP9701068A2 (hu) 1998-08-28
NO972816L (no) 1997-12-22
NZ328113A (en) 1999-09-29
MX9704579A (es) 1998-07-31
TR199700522A2 (xx) 1998-01-21
TR199700522A3 (tr) 1998-01-21
AU2612997A (en) 1998-01-08
HK1006081A1 (en) 1999-02-12
DE69710390D1 (de) 2002-03-21
ES2172744T3 (es) 2002-10-01
ID17051A (id) 1997-12-04
BR9703624A (pt) 1998-09-01
CZ187097A3 (cs) 1998-01-14
AU727851B2 (en) 2001-01-04
CN1132581C (zh) 2003-12-31
PL320628A1 (en) 1997-12-22
AR007609A1 (es) 1999-11-10
JP2009137970A (ja) 2009-06-25
HU9701068D0 (en) 1997-08-28
KR980000447A (ko) 1998-03-30
IL121076A (en) 2000-10-31
CZ290691B6 (cs) 2002-09-11
DE69710390T2 (de) 2002-08-14
CA2208199A1 (en) 1997-12-19
CN1173330A (zh) 1998-02-18
JPH1067663A (ja) 1998-03-10
US5977099A (en) 1999-11-02
PL188520B1 (pl) 2005-02-28
NO972816D0 (no) 1997-06-18
SG60073A1 (en) 1999-02-22
CA2208199C (en) 2006-10-24
PT813873E (pt) 2002-06-28
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
HUP9701068A3 (en) 2000-07-28
DK0813873T3 (da) 2002-05-27
KR100481254B1 (ko) 2005-09-12
RU2181287C2 (ru) 2002-04-20
NO313177B1 (no) 2002-08-26
JP4925074B2 (ja) 2012-04-25

Similar Documents

Publication Publication Date Title
ZA975335B (en) Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors.
ZA9710927B (en) Pharmaceutical composition.
ZA975947B (en) Aqueous-based pharmaceutical composition.
ZA9711508B (en) Rapidly disintegrable pharmaceutical composition.
ZA9710071B (en) Pharmaceutical composition.
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
ZA973022B (en) New pharmaceutical composition with anaesthetic effect.
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
ZA200005510B (en) Pharmaceutical composition.
HUP0004561A3 (en) Dihydrobenzofurans, pharmaceutical compositions containing them and use thereof
ZA977104B (en) Pharmaceutical compositions.
ZA989680B (en) Pharmaceutical composition.
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
DK0910369T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder
NO983802D0 (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmÕter
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
HUP0000203A3 (en) Naphthyl derivatives, pharmaceutical compositions containing them and intermediates
ZA987392B (en) Pharmaceutical composition.
AU1193199A (en) Arylpiperazines as serotonin reuptake inhibitors and 5-ht1dalpha antagonists
ZA972602B (en) Pharmaceutical compositions.
HUP0103006A3 (en) Substituted betha-diketones, pharmaceutical compositions containing them and their use
ZA974422B (en) Substituted-amidinobenzene derivative and pharmaceutical compositions thereof.